Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 4/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.42 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | JAK1 | P23458 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | IDH2 | P48735 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | MMP14 | P50281 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3492751 | 0.87 | GPBAR1 (0.36) | USP30 | |
| SCHEMBL3494555 | 0.83 | JAK2 (0.40) | MMP13ADAM17TGM2JAK2JAK1 | |
| SCHEMBL3493256 | 0.80 | MMP13 (0.45) | MMP13ADAM17TGM2JAK2JAK1 | |
| SCHEMBL3490742 | 0.79 | NAMPT (0.45) | MMP13ADAM17MMP2MMP14 | |
| SCHEMBL14155596 | 0.74 | NAMPT (0.45) | MMP13ADAM17GPR119MMP2MMP14 | |
| SCHEMBL27196781 | 0.73 | SYK (0.45) | TGM2OPRD1OPRK1GPR119TACR1 | |
| SCHEMBL26081084 | 0.73 | MGLL (0.46) | MMP13ADAM17OPRD1OPRK1GPR119 | |
| SCHEMBL26081086 | 0.72 | IDH1 (0.43) | TGM2GPR119TACR1IDH1IDH2 | |
| SCHEMBL30328592 | 0.72 | GPR119 (0.50) | GPR119 | |
| SCHEMBL3490987 | 0.71 | MAPT (0.46) | TGM2JAK2JAK1GPR119TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| EP-2125820-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | Astex Therapeutics Limited (GB) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008075110-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | GRK2, GNAO1, PTGER1 | MMP13 4272/4885ADAM17 4874/4885TGM2 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.